Kirin’s LC-Plasma Trial Reaches Completion: What Investors Should Watch Next
Kirin Holdings Company, Limited (KNBWY) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The clinical trial “A Randomized Controlled Trial Evaluating the Efficacy of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria in Preventing Upper Respiratory Tract Infections and Reducing Symptom Severity and Duration” tests whether a daily LC-Plasma tablet can lower the risk and impact of common upper respiratory infections in healthy people. For investors, it matters because it sits at the crossroads of immunity, consumer health, and functional foods, areas where Kirin Holdings has been growing beyond its traditional beverage roots.
The study tests LC-Plasma, a lactic acid bacteria dietary supplement developed to support immune function and help prevent upper respiratory tract infections. Participants take one 50 mg LC-Plasma tablet daily or a matching placebo, positioning the product as an easy-to-use, over-the-counter style immune health option if future data are positive.
This is a phase 3 interventional trial with randomized assignment, so volunteers are randomly placed into either the LC-Plasma or placebo group. It uses a parallel design and quadruple masking, meaning participants, doctors, trial staff, and outcome assessors do not know who gets LC-Plasma, aiming to keep the results objective and focused on prevention rather than treatment.
The study was first submitted on 2025-02-10, marking when the trial was formally registered and publicly disclosed. The latest update was filed on 2026-03-04, with the trial status now listed as completed, signaling that follow-up has ended and the focus can shift toward data cleaning, analysis, and potential publication or regulatory use.
If LC-Plasma shows clear benefits, Kirin Holdings (KNBWY) could strengthen its position in the growing immune health and functional supplement market, supporting a higher-quality earnings mix and better valuation multiples over time. Success could also pressure competitors in probiotics and immune health, such as large food and nutrition players, to defend share or accelerate their own clinical programs, which in turn could improve overall investor sentiment toward evidence-backed consumer health products.
Investors should note that no results are posted yet, so the near-term stock impact may be muted until data are released or commercial plans are clarified. Still, the completion and recent update of this phase 3 trial confirm that Kirin is executing on a health-science strategy that, if supported by strong outcomes, could provide a differentiated, defensible growth driver versus more commoditized beverage peers.
The study is now completed and recently updated, with further details and future results to be made available on the ClinicalTrials portal.
To learn more about KNBWY’s potential, visit the Kirin Holdings Company, Limited drug pipeline page.
